Literature DB >> 9931081

Autoantibodies to OxLDL are decreased in individuals with borderline hypertension.

R Wu1, U de Faire, C Lemne, J L Witztum, J Frostegård.   

Abstract

-Elevated antibody levels to oxidized low-density lipoprotein (aOxLDL) have been shown to correlate with the degree of atherosclerosis in some studies. On the other hand, immunization of experimental animals with OxLDL, leading to enhanced aOxLDL levels, inhibits the development of the disease. The role of antibodies to OxLDL during different stages of disease development is thus not clear. The objective of this study was to determine the level of aOxLDL in early cardiovascular disease, such as borderline hypertension (BHT). Seventy-three men with BHT were matched with 75 age-matched normotensive (NT) men (diastolic blood pressures, 85 to 94 and <80 mm Hg, respectively). Antibody levels to epitopes of OxLDL were determined by use of conventional and chemiluminescence ELISA techniques. Presence of carotid atherosclerosis was determined by B-mode ultrasonography; atherosclerotic plaques were detected in 29 individuals. BHT men had significantly lower aOxLDL levels of IgG class (P=0.001) and IgM class (P=0.001) than NT controls, as determined using chemiluminescence ELISA. Similar results were obtained using conventional ELISA, with which aOxLDL of IgG (P=0. 0002) and IgM (P=0.026) classes and antibody levels to malondialdehyde-LDL were significantly lower in BHT individuals. There was no difference in antibody levels between individuals with or without carotid atherosclerosis. It is not clear whether the decreased aOxLDL levels in BHT are due to a decreased immune reaction to OxLDL or to an increased consumption of aOxLDL due to binding to early atherosclerotic lesions. The possible implications of these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9931081     DOI: 10.1161/01.hyp.33.1.53

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  24 in total

Review 1.  Lipoprotein autoantibodies: measurement and significance.

Authors:  Gabriel Virella; Maria F Lopes-Virella
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

Review 2.  Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events.

Authors:  Adam Taleb; Joseph L Witztum; Sotirios Tsimikas
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

Review 3.  Intravenous immunoglobulin and atherosclerosis.

Authors:  Eiji Matsuura; Kazuko Kobayashi; Katsumi Inoue; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

4.  Relation between plasma oxLDL antibodies and oxLDL in the circulation.

Authors:  Yan Wang; Xueqiang Fang; Shumei Wang; Yueqiu Feng; Jinghai Yin
Journal:  Inflammation       Date:  2006-12-02       Impact factor: 4.092

Review 5.  Oxidized low-density lipoprotein biomarkers in atherosclerosis.

Authors:  Sotirios Tsimikas
Journal:  Curr Atheroscler Rep       Date:  2006-01       Impact factor: 5.113

6.  Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy.

Authors:  Gabriel Virella; Rickey E Carter; Antonio Saad; Edward G Crosswell; B Andrew Game; Maria F Lopes-Virella
Journal:  Clin Immunol       Date:  2008-06       Impact factor: 3.969

Review 7.  Atherogenesis and the humoral immune response to modified lipoproteins.

Authors:  Gabriel Virella; Maria F Lopes-Virella
Journal:  Atherosclerosis       Date:  2008-04-12       Impact factor: 5.162

8.  Lipid oxidation in carriers of lecithin:cholesterol acyltransferase gene mutations.

Authors:  Adriaan G Holleboom; Georgios Daniil; Xiaoming Fu; Renliang Zhang; G Kees Hovingh; Alinda W Schimmel; John J P Kastelein; Erik S G Stroes; Joseph L Witztum; Barbara A Hutten; Sotirios Tsimikas; Stanley L Hazen; Angeliki Chroni; Jan Albert Kuivenhoven
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09-27       Impact factor: 8.311

Review 9.  Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis.

Authors:  Calvin Yeang; Michael J Wilkinson; Sotirios Tsimikas
Journal:  Curr Opin Cardiol       Date:  2016-07       Impact factor: 2.161

10.  Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial.

Authors:  Bram J Geller; Jessica L Mega; David A Morrow; Jianping Guo; Elaine B Hoffman; C Michael Gibson; Christian T Ruff
Journal:  J Thromb Thrombolysis       Date:  2014-04       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.